Iberol

Quick links to important sections

Iberol

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Iberol

Quick Facts

Property Description
Active Ingredient Ferrous Sulfate (Elemental Iron)
Form Tablet (e.g., enteric-coated), Oral Solution, Syrup
Pharmacological Class Hematinic Agent, Iron Preparation
Common Use Replenishment of Iron Stores
Origin Synthetic Agent (Iron Salt)

What is Iberol and Its Pharmacological Class?

Iberol is a medicinal product or Mineral Supplement classified as an Iron Preparation and Hematinic Agent, intended for oral administration. This classification places it within the broader group of Antianemic Agents, distinguishing it as a supplier of the essential element iron. The product is a synthetic agent, specifically an Iron Salt, focused on providing elemental iron in a readily absorbable form. Ferrous Sulfate is widely clinically recognized as the standard compound for oral iron supplementation, often prescribed to individuals with nutritional deficiencies.

What is the Active Ingredient in Iberol and What Forms is it Available in?

The active ingredient in Iberol is Ferrous Sulfate (FeSO4), which serves as the most commonly used source of the required Elemental Iron (Fe(II)) for oral therapy. This active compound is confirmed to be widely used to manage iron deficiency. Iberol is manufactured in several Dosage Forms, addressing varied patient needs. These include standard oral tablets, specialized enteric-coated or delayed-release tablets, and liquid forms such as oral solution and syrup. These varied preparations are a differentiating feature for the product line, ensuring that diverse populations can use the medicine effectively via the oral route of administration.

What is the General Purpose of This Hematinic Agent?

The general purpose of Iberol is to facilitate the body’s Replenishment of Iron stores, ensuring the necessary substrate is available for biological function. Iron is integral to the synthesis of Hemoglobin and Myoglobin, which are crucial for systemic Oxygen Transport to muscles and tissues. Oral iron supplements are used to improve iron status. This fundamental action supports Red Blood Cell Production, providing a general benefit of countering the common fatigue and weakness associated with iron insufficiency.

Regulatory References

  1. DailyMed: Ferrous Sulfate Label

What side effects are possible with Iberol?

Iberol is not a recognized drug name with an official, publicly documented safety profile released by major governmental regulatory authorities such such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Consequently, there are no available regulatory labels detailing its adverse reactions, warnings, or risk management structure.

Adverse Reaction Scope

Classification Regulatory Status for Iberol
Key Adverse Reaction Categories None officially documented in government regulatory texts.
Frequency Classification No formal frequency classifications (e.g., very common, rare) are available.
System-Organ Classes Involved No specific System-Organ Classes (SOCs) for side effects are documented.
Serious Adverse Reactions No serious adverse reactions are formally documented by major regulatory bodies.
Population-Specific Considerations No population-specific safety information is documented.
Dose- or Exposure-Related Patterns No patterns related to dose or exposure are explicitly stated.
Safety-Related Restrictions/Limitations No specific restrictions or limitations are formally documented.

Safety Classifications (High-Level)

  • Regulatory Basis: The safety profile is not established in publicly accessible governmental drug labels from the FDA or EMA.
  • Safety Monitoring Notes: There are no high-level safety monitoring instructions defined in official regulatory documents for this drug name.

Connection to the Overall Safety Profile

Because the name Iberol does not correspond to a medicine with a published regulatory approval and safety label, the official understanding of its risks is a null profile. This means that a standard, officially defined structure of potential side effects, including serious adverse events and required monitoring, is not available through primary governmental regulatory sources. Any risk assessment must therefore rely on non-governmental or non-official clinical information, which falls outside the scope of formal regulatory safety summaries.

Overdose and Emergency Response

Ferrous sulfate overdose is officially documented as presenting with a serious, sequential pattern of toxicity. Initial manifestations typically involve gastrointestinal distress, including vomiting, diarrhea, abdominal pain, and sometimes abnormal stool coloration. This early stage may be followed by a temporary clinical improvement before escalating to severe systemic effects. Officially documented life-threatening outcomes include shock, metabolic acidosis, liver failure (hepatic necrosis), and coma.

The regulatory profile classifies this as a high risk of severe and fatal poisoning, particularly noting that accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under six years of age. Due to this severe risk, immediate medical intervention is mandated. Individuals must seek emergency medical attention and call a doctor or Poison Control Center immediately upon suspected or confirmed overdose.

Specific management procedures, as described in regulatory documents, require immediate support of the airway, breathing, and circulation, as well as the potential use of the specific iron chelating agent, Deferoxamine, guided by monitored serum iron levels. The regulatory guidance emphasizes that treatment involves specific procedural steps like gastric lavage and continuous monitoring of vital signs and laboratory parameters to address the staged toxicity.

Therapeutic Uses of Iberol

Supportive care is a recognized therapeutic approach used to manage the effects of illness, symptoms, and side effects. Iberol may assist with managing certain symptoms, and is considered relevant in situations where symptoms appear suddenly or intensify quickly. Iberol may be applicable for conditions involving symptoms related to systemic imbalance, heightened physiological activity, and functional stress linked to episodic or fluctuating manifestations. This support is relevant when short-term symptomatic assistance is needed during phases of increased distress or when symptoms create noticeable functional strain. This assistance contributes to supporting comfort during symptomatic periods, and helps patients cope more steadily with symptom fluctuations.

“It helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Supports in easing Physical Discomfort

Regulatory References

  1. National Cancer Institute definition of Supportive Care

Eligibility and Restrictions for Use

Eligibility Scope and Restrictions

Iberol (Ferrous Sulfate) is generally permitted for use by Adults and Adolescents aged 12 years and over. Its use is strictly defined by regulatory documents based on a patient's iron status and specific medical history.

Contraindicated Populations (Must Not Use)

Official labeling contraindicates the use of Iberol in patients with conditions that pose a risk of iron overload, such as hemochromatosis and hemosiderosis. Use is also forbidden in patients receiving repeated blood transfusions.

Additionally, the medicine is contraindicated for individuals with certain active gastrointestinal diseases, including peptic ulceration, ulcerative colitis, and regional enteritis.

Age-Related and Conditional Rules

Use is not recommended for standard adult tablet strengths in children under 12 years. All iron products carry a prominent regulatory warning concerning the risk of fatal accidental poisoning in children under 6 years, which restricts unsupervised use in this group.

Regarding Pregnancy, use is often permitted after the first 12 weeks, but use during the first 12 weeks is restricted and requires specific recommendation based on established deficiency. Use while breastfeeding is generally considered acceptable, but professional advice should be sought.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ferrous Sulfate (Iberol) is officially documented to interact with various medicinal products and substances, primarily through altering absorption. These interactions are classified as clinically significant and necessitate specific regulatory constraints.

Mandatory Timing and Contraindications

Co-administration with several medicines requires a specific time separation to prevent a reduction in systemic exposure. For instance, regulatory labeling requires that Quinolone antibiotics (such as Ciprofloxacin) be administered at least two hours before or six hours after the iron product. Doses of Levothyroxine must also be separated by at least two hours. The combination of Ferrous Sulfate and Doxycycline is restricted, and some official regulatory sources classify this specific combination as contraindicated.

Exposure Reduction of Co-Administered Drugs

Official documents state that iron can significantly decrease the systemic absorption and subsequent exposure of several critical agents, including Tetracycline antibiotics, Levodopa, Methyldopa, and Bisphosphonates. This reduction is primarily due to the inhibition of gastrointestinal absorption. Additionally, Ferrous Sulfate can reduce the absorption of Zinc supplements.

Interactions Reducing Iron Absorption

Certain substances and dietary components can reduce the absorption of Ferrous Sulfate. Agents that increase gastric pH, such as Antacids, H2 Receptor Blockers, and Proton Pump Inhibitors, are documented to decrease iron bioavailability. Furthermore, foods and beverages containing high levels of phytates, calcium, or polyphenols—including dairy products, coffee, tea, and whole-grain breads—may impair oral iron absorption.

Mechanism of Action

Substrate Provision and Molecular Transport

The primary action is the provision of the ferrous ion ( Fe^2+), which is actively transported across the intestinal barrier via specialized proteins, including DMT1 and Ferroportin. Once absorbed, the Fe^2+ is bound by Transferrin and delivered to the bone marrow where it serves as the crucial structural component for the synthesis of Hemoglobin (Hb) and Cytochrome enzymes.


Modulation of Oxygen Delivery Pathways

By ensuring the necessary substrate is available, the drug supports the Erythropoiesis pathway, enabling the bone marrow to produce hemoglobinized red blood cells. This mechanistic cascade directly increases the blood’s systemic oxygen-carrying capacity and supports Myoglobin function in muscle tissue, thereby modulating metabolic and transport pathways.


Bioregulatory Constraints on Absorption

The efficiency of this mechanism is inherently regulated by the body's Hepcidin-Ferroportin axis, a natural negative feedback loop. The release of Hepcidin in response to absorbed iron temporarily reduces the functionality of Ferroportin, intrinsically limiting the percentage of subsequent doses that can be taken up. This regulatory constraint influences the overall time course of physiological change.

Dosage and Administration Information

Iberol is an iron preparation used exclusively via the oral route of administration for all its approved forms, which include standard tablets and liquid solutions. The standard adult therapeutic regimen involves taking 200 mg of ferrous sulfate in 2 to 3 divided doses daily, although a simpler 200 mg once daily regimen is typically applied for prophylactic use.

Optimal absorption of the iron compound occurs when the medicine is taken on an empty stomach, generally 1 hour before or 2 hours after meals. Administration involves specific procedures: tablets, particularly specialized extended-release forms, must be swallowed whole with water and must not be sucked, crushed, or chewed. This procedural requirement ensures the intended release pattern and prevents damage to the esophagus.

General instructions include avoiding the consumption of liquids like milk, tea, or coffee for at least 2 hours around the time of dosing, as these substances can interfere with the elemental iron uptake. Treatment duration often extends for several months and is required to continue for approximately 3 months after the correction of anemia to fully replenish the body's iron stores. The 200 mg tablet is not recommended for children under 12 years; liquid forms are prescribed based on age and weight for younger patients. If a dose is missed, it is generally advised to simply take the next dose at the regular time and avoid doubling the amount.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Iberol (Ferrous Sulfate)


Evidence for Use in Iron Deficiency Anemia (IDA)

Research examining Iberol for IDA primarily consists of short-term Randomized Controlled Trials (RCTs) and systematic reviews that compare ferrous sulfate to a placebo or other iron formulations. These studies monitored populations including adults and children diagnosed with IDA. The main goals of the research were to measure changes in markers like hemoglobin (Hb) and serum ferritin, which were utilized in the studies to track the body’s iron status and the progress of observed changes in anemia markers.

The studies reported measurements of changes in hemoglobin and serum ferritin levels over defined treatment periods, typically lasting 8 to 12 weeks. Research also explored the outcomes and reported side effects related to oral iron in patients who have other complex conditions, such as Chronic Kidney Disease (CKD) and Inflammatory Bowel Disease (IBD). A pattern described across various trials was the reporting of gastrointestinal-related issues among participants receiving oral iron, which was described in study reports as potentially affecting treatment completion.

Research on Preventing Iron Deficiency During Pregnancy

Studies for preventing iron deficiency in pregnancy mainly involved RCTs assessing routine iron supplementation compared to either a placebo or no supplement in women who were not anemic at the start of the study. Research examined maternal outcomes such as the trajectory of hemoglobin and ferritin levels and explored various infant health outcomes, including the incidence of low birth weight or preterm birth.

Trials reported patterns where measurements of maternal iron status markers were observed, with differences described in the rate at which they shifted into the deficient range when compared to placebo. However, official reviews have noted that the evidence remains insufficient to fully characterize the balance of effects (benefits versus potential harms) for routine daily iron supplementation in all non-anemic pregnant women.

Long-Term Studies and What is Still Uncertain

The majority of research exploring iron supplementation has focused on short-term treatment phases lasting between 8 to 12 weeks. Evidence for the long-term duration of the change in iron status is not fully established. Follow-up durations were limited in many studies, meaning that data are still emerging regarding the risk of iron deficiency recurring after the study regimen is complete. Research is ongoing to address the high heterogeneity (variability) noted across different trials. Study results reflect the specific conditions under which they were conducted and do not determine whether an individual will respond similarly.

Key Studies & References

  1. SUMMARY OF EVIDENCE - Oral Iron for Anemia: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines

Frequently Asked Questions (FAQ)

Common questions about Iberol (FAQ)


Q: Is Iberol the same type of medicine as [similar drug name]?

A: Iberol’s active ingredient, Ferrous Sulfate, is officially classified as an Iron Preparation or Hematinic Agent. This places it within the category of medicines intended to supply the essential mineral iron to the body. This classification distinguishes it from other types of substances.


Q: What are the most commonly reported side effects of Iberol?

A: According to official product information, commonly reported side effects are primarily gastrointestinal-related. These may include nausea, stomach discomfort, constipation, or diarrhea. Stools may also appear dark or black, which is a change often associated with unabsorbed iron.


Q: How long does it typically take for Iberol to start working?

A: Studies and official information indicate that noticeable changes in markers or symptoms may begin after about 3 to 4 weeks of treatment. Full restoration of the body's essential iron stores is often observed after 2 to 4 months, as the physiological change takes time.


Q: Can Iberol be taken by older adults?

A: The use of the active ingredient by adults, including older adults, is generally permitted. Regulatory warnings caution that elderly patients or those with difficulty swallowing may be at greater risk of throat or esophageal ulceration if the tablet becomes lodged. Administration requirements indicate that tablets should be swallowed whole with water, not crushed or chewed.


Q: Does Iberol interact with common over-the-counter pain relievers?

A: Official regulatory labels generally do not list a direct interaction between the active ingredient and common non-prescription pain relievers such as ibuprofen or acetaminophen. It is standard practice for a healthcare provider to be informed of all medicines and supplements being taken.


Q: Is Iberol considered a controlled substance?

A: No. The active ingredient in Iberol, ferrous sulfate, is not classified as a controlled substance by the U.S. Drug Enforcement Administration or equivalent regulatory bodies.


Q: Will Iberol affect my ability to drive or operate machinery?

A: Regulatory documents do not typically include a warning that this medicine directly impairs the ability to drive or operate heavy machinery. If general side effects such as dizziness or lightheadedness occur, official information suggests that effects on driving should be monitored.


Q: Can Iberol cause problems with sleep?

A: Official regulatory labels and documents do not commonly list sleep disorders, such as insomnia or drowsiness, among the reported side effects for the active ingredient.


Q: Does Iberol affect laboratory blood test results?

A: Yes, regulatory information indicates that the active ingredient may interfere with certain laboratory tests. This most commonly applies to the fecal occult blood test (FOBT), where it may potentially cause false positive results. For accurate interpretation of results, lab personnel typically require information about iron product use.


Q: Can I take Iberol if I am already taking an antibiotic?

A: It is possible to take Iberol with some antibiotics, but the regulatory text indicates that oral iron products and certain antibiotics, like tetracyclines, require a time separation of at least two hours for each to be absorbed properly. This is to avoid interference with the absorption of the iron or the antibiotic.


Q: Does alcohol change the way Iberol works in the body?

A: Official regulatory guidance notes that it is unknown if alcohol directly affects iron absorption. Both iron products and alcohol can potentially cause or worsen stomach upset.


Q: What is the risk of a serious allergic reaction to Iberol?

A: Although serious allergic reactions are rare, like any medicine, the active ingredient can cause one. Official guidance indicates that if signs such as a severe rash, swelling of the face/throat, or difficulty breathing occur, medical assistance is generally required.


Q: Is Iberol approved for use in conditions other than [main approved condition]?

A: The primary approved uses are for Iron Deficiency Anemia and related conditions. Regulatory bodies also recognize its use in conditions like Anemia Due to Chronic Kidney Disease and for Vitamin/Mineral Supplementation during Pregnancy.


Q: Are there long-term side effects associated with taking Iberol?

A: Regulatory labels describe the risk of iron overload (hemosiderosis) associated with prolonged or excessive intake. The required treatment duration is typically limited to the time necessary to correct the iron deficiency.


Q: Why does the packaging for Iberol contain a specific warning?

A: Regulatory requirements mandate that the packaging carry a prominent BOXED WARNING. This warning states that the accidental overdose of iron-containing products is a leading cause of fatal poisoning in young children.


Q: What if Iberol doesn't seem to be working for me?

A: Regulatory text indicates that the management of any anemic condition typically occurs under the advice and supervision of a doctor. If the expected effect is not observed, the patient’s condition should be monitored more closely to assess the cause of the subtherapeutic effect.


Q: Are there specific vitamins or herbal products that interact with Iberol?

A: Some supplements interact with the iron compound. Regulatory documents note that Calcium and Zinc supplements can reduce the absorption of iron. The use of other vitamins or herbal products alongside iron products typically involves a discussion with a healthcare professional.


Q: Is Iberol safe for people with liver disease?

A: Iron products are contraindicated (must not be used) in patients with conditions that pose a risk of iron overload such as hemochromatosis. Caution is also advised when using liquid products if a patient has a history of liver disease or alcohol dependence.


Q: What does the term 'contraindication' mean for Iberol?

A: A contraindication is a specific medical condition or situation where the medicine must not be used because the risk of harm outweighs any potential benefit. For Iberol, examples include a known hypersensitivity to the ingredients or conditions that cause iron overload.


Q: How do I know if the side effects I am having are normal for Iberol?

A: Common side effects, such as nausea or constipation, are usually temporary and tolerable. If signs of a severe allergic reaction occur, or if side effects are severe, persistent, or cause significant concern, consultation with a healthcare professional is generally required.


Q: Have there been any recent changes to the safety warnings for Iberol?

A: Regulatory bodies continually monitor and update safety information for the active ingredient. Any changes to warnings or other safety information are formally detailed in the Revision History or Updates section of the official regulatory label, which serves as the most current source of information.


Q: Can taking Iberol cause stomach upset?

A: Yes, occasional gastrointestinal discomfort is a commonly reported side effect, which may include nausea, constipation, diarrhea, or stomach pain. The product information notes that occasional gastrointestinal discomfort is a commonly reported side effect.


Q: Is Iberol safe for use during pregnancy or breastfeeding?

A: Official documentation states that if a person is pregnant or nursing a baby, they should consult a health professional before using this product. Use during the first trimester of pregnancy may be restricted, but it is often permitted after the first 12 weeks for iron deficiency.


Q: Where can I find the official patient information leaflet for Iberol?

A: Official patient information leaflets (PIL) or drug labels (SPL) for products containing the active ingredient are typically available on governmental public repositories. These include websites such as DailyMed (NIH/FDA) or the MHRA/emc website.


Q: Are mood changes a reported side effect of Iberol?

A: Official regulatory labels and summaries do not commonly list mood changes, such as anxiety or depression, among the reported side effects for the active ingredient.


Q: Do I need a special diet while taking Iberol?

A: A comprehensive 'special diet' is not required, but regulatory documents describe important timing restrictions. Substances like dairy products, coffee, or tea can significantly reduce iron absorption, and time separation is typically required when taking the medicine.


Q: What type of monitoring is needed when taking Iberol?

A: To monitor the effectiveness of the treatment and ensure the patient is benefiting, regulatory guidance suggests that lab tests may be performed. These typically include measuring markers like complete blood count (CBC), hemoglobin (Hb), and serum ferritin levels.


Q: What happens if I take more Iberol than the recommended amount?

A: An overdose of iron can be fatal, especially in young children. Regulatory guidance describes that if an overdose is suspected, emergency medical attention is required, often involving a Poison Control Center or a doctor.

How should Iberol be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documents define the mandatory conditions for storing Iberol to ensure product stability and safety.

Storage Domain Official Requirement
Temperature Store at controlled room temperature (e.g., 20 C to 25 C). Do not refrigerate or freeze.
Protection Keep the product in the original container and protect it from moisture and light.
Handling Keep this medicine strictly out of the sight and reach of children.
Disposal Do not dispose of expired or unused medicine in household trash or wastewater.

Disposal must follow local pharmaceutical take-back programs or collection events, as advised by governmental sources, to protect the environment and ensure proper handling of unused medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Iberol found in:

A-Z Index: